biopsy and evaluation by the dermatology consult service. Cutaneous features with respect to lesion morphology, location, and time of onset following transplantation were collected for each patient and further stratified by aGVHD clinical grade. Results: For all cutaneous aGVHD patients (n¼37), the onset of rash was on average, day +45 (range +4 to +153). The most common skin lesion morphology was morbilliform (55%) followed by patchy erythema (38%). Follicular accentuation was seen in 29% of rashes. The cutaneous eruptions most commonly occurred on the trunk (69%), arms/legs (67%), face (62%), ears (38%) and palms (38%). Comparing grade I and II skin aGVHD patients, grade I patients (n¼11) had more patchy erythema (73% vs 23%,P ¼ .008), purpuric/violaceous lesions (55% vs 15%,P ¼ .038) or a reticular pattern (36% vs 0%,P ¼ .005) than grade II patients (n¼26). Grade II aGVHD patients were found to have cutaneous eruptions located more often on the trunk (85% vs 36%,P ¼ .006) and arms/legs (77% vs 36%,P ¼ .028) when compared to grade I aGVHD patients. Comparison to grade III (n¼3) and IV (n¼2) aGVHD patients was not performed given the paucity of cases. Conclusion: We profiled the salient cutaneous features associated with aGVHD and their relative incidences based on clinical grade, skin lesion morphology and anatomic site of involvement. Application of this analysis will allow for improvements in the diagnosis of aGVHD and differentiation from other clinical mimickers. Differences in lesional morphology and location may differentiate grade I and II cutaneous aGVHD and serve to guide appropriate treatment.
biopsy and evaluation by the dermatology consult service. Cutaneous features with respect to lesion morphology, location, and time of onset following transplantation were collected for each patient and further stratified by aGVHD clinical grade. Results: For all cutaneous aGVHD patients (n¼37), the onset of rash was on average, day +45 (range +4 to +153). The most common skin lesion morphology was morbilliform (55%) followed by patchy erythema (38%). Follicular accentuation was seen in 29% of rashes. The cutaneous eruptions most commonly occurred on the trunk (69%), arms/legs (67%), face (62%), ears (38%) and palms (38%). Comparing grade I and II skin aGVHD patients, grade I patients (n¼11) had more patchy erythema (73% vs 23%,P ¼ .008), purpuric/violaceous lesions (55% vs 15%,P ¼ .038) or a reticular pattern (36% vs 0%,P ¼ .005) than grade II patients (n¼26). Grade II aGVHD patients were found to have cutaneous eruptions located more often on the trunk (85% vs 36%,P ¼ .006) and arms/legs (77% vs 36%,P ¼ .028) when compared to grade I aGVHD patients. Comparison to grade III (n¼3) and IV (n¼2) aGVHD patients was not performed given the paucity of cases. Conclusion: We profiled the salient cutaneous features associated with aGVHD and their relative incidences based on clinical grade, skin lesion morphology and anatomic site of involvement. Application of this analysis will allow for improvements in the diagnosis of aGVHD and differentiation from other clinical mimickers. Differences in lesional morphology and location may differentiate grade I and II cutaneous aGVHD and serve to guide appropriate treatment. Background: Lipoxins (derived from arachidonic acid) and the resolvins and protectins (derived from u3-polyunsaturated fatty acids (PUFAs)) are endogenously produced lipid mediators with potent anti-inflammatory and tissue healing properties. Acetylsalicylic acid (ASA, aspirin) results in the synthesis of aspirin-triggered lipoxins, isomers for these lipid mediators with identical anti-inflammatory actions. In part, these lipid mediators act through downregulation of Th1 cytokines known to be important in aGVHD pathogenesis. The C56BL/6/(C57BL/6 x DBA/2)F 1 -hybrid is a major histocompatibility mismatched mouse model of lethal aGVHD (similar to a non T-cell depleted HLA haploidentical BMT without GVHD prophylaxis) that allows isolation of the aGVHD effect. We wanted to test whether these novel lipid mediators could attenuate aGVHD in this highly inflammatory allogeneic transplant mouse model. Methods: Mice were transplanted according to standard protocols. Four diets were created, including a control diet containing 2% u6-PUFAs; and three experimental diets, enriched for (1) 2% u3-PUFAs (2) 2% u6-PUFAs plus ASA (0.02 mg/g of feed) (3) 2% u3-PUFAs plus ASA. Mice were randomly fed one diet (n¼10-12 per group) for 8-weeks before transplant and the same diet after transplant. A separate experiment confirmed that feeding the different diets for 8weeks before transplant resulted in differential tissue (liver) stores of u6and u3-PUFAs. A fifth group (n¼10) was fed the control diet but injected with the aspirin-triggered lipoxin 15-epi-LxA4 IV on day 0 and IP on day 7 (200 mcg/kg/dose). The primary outcome was days before the onset of aGVHDassociated morbidity (humane end point) post-transplant. Results: Control GVH mice met the humane end-point for euthanasia as result of aGVHD at a median of 14 days posttransplant (range: 9-16 days). Kaplan-Meier survival curves showed modest but statistically significant improvements in survival for mice fed a diet enriched for u3-PUFAs plus ASA (P ¼ .0117) and mice receiving the aspirin-triggered lipoxin (P ¼ .034) compared to the control group. Survival improvements and the onset of lethal aGVHD were delayed by a matter of days for the mice receiving the interventions.
Conclusion:
We provide proof-of-principle that dietary u3- CGVHD develops in more than 50% of survivors of allogeneic stem cell transplantation and is responsible for mortality in one third of patients. Long term immunosuppressive therapy with steroids is the standard treatment. ECP has shown activity in acute and cGVHD and is successful in about 50% of the patients after 3 e 6 months of therapy. We studied the cytokine profiles in 6 patients with cGVHD undergoing ECP. A comprehensive assessment of organ system involvement using NIH Consensus response assessment tools was done at study entry and at six months. Patients underwent ECP treatments twice on two consecutive days every two weeks for 3 to 6 months. All patients underwent baseline, twomonths, four months and six-month assessments. 10 ml of leukopheresed blood was obtained from the ECP machine prior to the initiation of ECP at baseline, and at 2, 4 and 6 months post treatment to assess peripheral blood B and T cells and the cytokine analysis. CD4 + T cells were purified from PBMCs and stimulated with anti-CD3 and anti-CD28 for five days. Tissue culture supernatants were collected and analyzed for the production of 42 cytokines using LuminexÒ technology. Three patients responded to treatment with ECP and three did not and later received other therapies. We have previously reported that responding patients had higher CD4+CD25+FoxP3+ cells. Of the cytokines analyzed, soluble CD25 and TNFb were secreted at significantly higher levels in responding patients prior to ECP initiating therapy (Figure) . In responders, sCD25 and TNFb levels remained high Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341 S322
